← Back to Search

Decision Aid for Lung Cancer

Waitlist Available
Led By Donald Sullivan
Research Sponsored by OHSU Knight Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Completed treatment for suspected or confirmed stage I-IV non-small cell lung cancer (NSCLC)
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to the end of follow-up at 8 weeks
Awards & highlights

Study Summary

This trial is testing a decision aid to help patients with non-small cell lung cancer make better decisions about their care. The goal is to improve patient involvement, satisfaction, and communication with their physician.

Who is the study for?
This trial is for English-speaking individuals with a life expectancy over 6 months who have completed treatment or are undergoing diagnostic work-up for suspected or confirmed stage I-IV non-small cell lung cancer. They must also be cognitively able to participate, as indicated by a score above 3 on a specific cognitive screener.Check my eligibility
What is being tested?
The study tests the effectiveness of a decision aid designed to improve decision-making in patients with non-small cell lung cancer. It aims to see if this tool helps patients understand their condition better and make more informed choices about their care alongside their doctors.See study design
What are the potential side effects?
Since the interventions include best practices, informational intervention, and questionnaire administration rather than medical treatments, there are no direct physical side effects expected from participating in this trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I have completed treatment for early or advanced non-small cell lung cancer.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and at enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Acceptability of the conversation tool
Feasibility of the conversation tool
Secondary outcome measures
Decision making involvement
Decisional Regret
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (conversation tool)Experimental Treatment2 Interventions
Patients receive the conversation tool.
Group II: Arm II (usual care)Active Control2 Interventions
Patients receive usual care.

Find a Location

Who is running the clinical trial?

Hildegard Lamfrom EndowmentUNKNOWN
Medical Research Foundation, OregonOTHER
12 Previous Clinical Trials
988 Total Patients Enrolled

Media Library

Informational Intervention Clinical Trial Eligibility Overview. Trial Name: NCT04946279 — N/A
Non-Small Cell Lung Cancer Research Study Groups: Arm I (conversation tool), Arm II (usual care)
Non-Small Cell Lung Cancer Clinical Trial 2023: Informational Intervention Highlights & Side Effects. Trial Name: NCT04946279 — N/A
Informational Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT04946279 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are researchers seeking new participants for this investigation?

"Affirmative. Clinicaltrials.gov confirms that this medical study, originally posted on August 7th 2020, is actively welcoming new patients to participate. Around 100 participants will be accepted at two separate sites of research."

Answered by AI

What is the enrolment tally for this research endeavor?

"Affirmative, the clinicaltrials.gov portal indicates that this research initiative is actively recruiting participants. This trial was first posted on August 7th 2020 and revised most recently on June 8th 2022; they are still in need of 100 individuals across two sites."

Answered by AI

What is the primary objective of this medical research endeavor?

"The main metric of measurement during this trial is the operational feasibility of a conversation tool. Secondary outcomes include decisional conflict (measured through Decisional Conflict Scale), patient involvement in treatment decisions (through Control Preferences Scale) and values-treatment concordance (assessed via Electronic Medical Record)."

Answered by AI
~22 spots leftby Jun 2025